Using engineered nanoparticles to improve cancer treatment by modulating the immune system
Official title: Engineered Nanoformulation for Immune-modulation in Cancer
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-10907737 · Data updated 2026-11-12
This study is looking at how tiny particles can help boost your immune system to fight cancer better by blocking certain proteins that stop your immune cells from working, which could lead to new and more effective treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $535,400 |
| NIH project number | 5R01CA282735-02 |
| Project ID | NIH-10907737 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that express immune checkpoint proteins and who may not have responded well to conventional therapies.
✕Less likely to help
Patients with early-stage cancers that are easily treatable with standard therapies may not receive significant benefit from this research.
What this research studies
This research investigates how engineered nanoformulations can enhance the immune response against cancer by targeting immune checkpoint molecules that inhibit T-cell activity. The approach involves using lipid-based nanoparticles to deliver siRNA that silences specific proteins in cancer cells, potentially leading to improved tumor eradication. By understanding the interaction between cancer drugs and immune checkpoints, the research aims to develop new therapies that can overcome treatment failures. Patients may benefit from more effective cancer treatments that harness their immune system's capabilities.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that improve patient outcomes and survival rates.
How similar studies have gone: Previous studies have shown promising results with similar approaches using immune checkpoint inhibitors and targeted therapies in cancer treatment.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Ramesh, Rajagopal — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Ramesh, Rajagopal
Related research
Other NIH-funded projects on the same topics.
-
Primary care research network in Oklahoma to boost rural patient trials
A nationwide NIH-supported effort to strengthen Oklahoma’s primary care research network so doctors can run big clinical trials and real‑world studies in rural communities.
-
N-myristoylation and DNA damage response in Alzheimer’s disease
A study to understand how a protein modification called myristoylation affects the DNA damage response in people who have Alzheimer’s-related conditions.
-
Genetically engineered mouse model to study and treat high-risk pediatric rhabdomyosarcoma
A research project aims to create mouse models that mimic high-risk pediatric rhabdomyosarcoma and test therapies that target the NOTCH1 pathway to slow or stop tumor growth.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
TFEB as a key switch to keep muscles healthy as we age
A study in aging adults and aging muscle tissues looks at whether boosting TFEB can improve how muscles maintain themselves and recover after disuse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.